Key Highlights

  • Addex Therapeutics Penny Stock is trading at $2.88 in pre-market activity, down 3.30% from Thursday's close of $2.98.
  • Jean-Philippe Rocher returns as Head of Pharmaceutical Development and joins the executive management.
  • Mikhail Kalinichev is stepping down as Head of Translational Science to focus on a similar role at the spin-out Neurosterix.
  • The stock gained 7.97% on Thursday, so the pre-market dip follows a sharp rally.

A Leadership Reshuffle Meets a Stock Giving Back Some of Thursday's Gain

Addex Therapeutics (NASDAQ:ADXN), a penny stock from a Geneva-based clinical-stage company developing small-molecule allosteric modulators for neurological disorders, is slipping in pre-market trading after announcing executive changes. Shares are at $2.88, down 3.30% from Thursday's close of $2.98, which itself followed a 7.97% gain.

A personnel announcement is an unlikely main driver of a move this size. Early Volume is light, and the dip looks as much like a pullback after Thursday's jump as a reaction to the news.

A Founding Chemist Returns as the Pipeline Prepares to Move

Rocher brings more than 30 years of drug discovery experience and has deep history with the company. He joined at its inception in 2002, helped build its chemistry platform and played a role in drugs that reached Phase 2 development. He later moved to Neurosterix after its 2024 spin-out and retired from that role before returning to Addex.

Rocher said he is rejoining at a pivotal time, after the company regained rights to its GABAB PAM program from a partner, with several drug candidates ready to begin clinical development. CEO Tim Dyer said his expertise will help guide the next phase of the clinical plan.

The Translational Science Lead Leaves for the Spin-Out

Kalinichev decided to step down so he can focus on a similar position at Neurosterix, the private spin-out in which Addex holds a 20% Equity interest. The company thanked him for his contribution to its pipeline and to the founding of the spin-out. The announcement does not say who will take over his translational work.

Thin Trading and a Steep Fall From the Highs Limit What a Personnel Story Can Do

The weak points are plain. There is no clinical or financial news in the release, early volume is thin, and at $2.88 the shares trade about 76% below their 52-week high of $11.97, only modestly above the low of $2.56. In a stock like this, small trades can move the price a few percent either way.

On the supportive side, the company has a lead drug, dipraglurant, ready for a Phase 2 trial in brain injury recovery, a GABAB program that has completed studies needed to apply for human testing, and a stake in a spin-out advancing separate programs. The appointment adds experience in moving candidates toward the clinic.